Emily Tsaroucha
About
In The Last Decade
Emily Tsaroucha
10 papers receiving 559 citations
Peers
Comparison fields: 5 of 60
- Molecular Biology 492
- Cancer Research 441
- Oncology 65
- Pulmonary and Respiratory Medicine 56
- Physiology 27
Countries citing papers authored by Emily Tsaroucha
This map shows the geographic impact of Emily Tsaroucha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Tsaroucha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Tsaroucha more than expected).
Fields of papers citing papers by Emily Tsaroucha
This network shows the impact of papers produced by Emily Tsaroucha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Tsaroucha. The network helps show where Emily Tsaroucha may publish in the future.
Co-authorship network of co-authors of Emily Tsaroucha
This figure shows the co-authorship network connecting the top 25 collaborators of Emily Tsaroucha. A scholar is included among the top collaborators of Emily Tsaroucha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Tsaroucha. Emily Tsaroucha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 14 | |
| 3 | 26 | |
| 4 | 2 | |
| 5 | 70 | |
| 6 | Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) | 2 |
| 7 | Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer. | 8 |
| 8 | 380 | |
| 9 | 28 | |
| 10 | 1 | |
| 11 | 38 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.